AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

Sales of AstraZeneca’s key medicines, mainly cancer drugs — Lynparza, Tagrisso and Imfinzi — and diabetes medicine Farxiga are expected to have driven the company’s top line in the fourth ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Hector expects AstraZeneca (NASDAQ:AZN) to guide towards a high-single-digit revenue growth for 2025, which would factor in the anticipated effects of Farxiga generics in China. The specifics of ...

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

So if actually AstraZeneca was found liable ... specifically Tagrisso and Farxiga as well as demand for our respiratory products that is lower given the mild start of the winter.

DAVENPORT & Co LLC decreased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...